Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 ‘CaboGIST’
Nom du journal : Eur J Cancer
Année : 2020
Volume : 134
Page de départ : 62
Page de fin : 74